文献速递白血病

慢性髓性白血病患者接受三线BCR::ABL1酪氨酸激酶抑制剂治疗的结局

The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
PubMed 文献 · Am J Hematol · 2023-01-31

该研究分析了354例慢性期慢性髓性白血病(CML-CP)患者,分别在本机构及PACE和OPTIC试验中接受三线BCR::ABL1酪氨酸激酶抑制剂(TKI)治疗,比较替代二代TKI与帕纳替尼的结局。倾向性评分匹配和多因素分析显示,帕纳替尼组3年无进展生存率和总生存率均优于二代TKI组,帕纳替尼是三线治疗中唯一与更好生存相关的独立因素。

要点

  • 帕纳替尼组3年无进展生存率83% vs 二代TKI组59%(p < .001)。
  • 帕纳替尼组3年总生存率87% vs 二代TKI组83%(p = .03)。
  • 多因素分析显示帕纳替尼是三线治疗中唯一与更好生存相关的独立因素(p = .003)。

核心结论

  • 帕纳替尼是经两种 prior TKI 治疗失败的CML-CP患者的优化治疗选择。

研究设计与样本

  • 研究分析了354例CML-CP患者,来自本机构及PACE和OPTIC试验,均接受三线BCR::ABL1 TKI治疗。
  • 采用倾向性评分匹配比较结局,多因素分析识别与生存相关的变量。

主要发现

  • 173例(49%)接受二代TKI,181例(51%)接受帕纳替尼。
  • 帕纳替尼组心血管危险因素更多(34% vs 19%),疾病负荷更高(BCR::ABL1转录本>1%:165/175 [94%] vs 75/135 [55%];p < .001)。
  • 帕纳替尼组173例可评估患者中89例(52%)达到基线转录本2-log及以上下降(20%达2-log下降,32%达3-log及以上下降)。
  • 二代TKI组128例可评估患者中44例(34%)达到基线转录本2-log及以上下降(13%达2-log下降,21%达3-log及以上下降)。
  • 中位随访46个月,3年无进展生存率:二代TKI组59%(匹配前60%)vs 帕纳替尼组83%(匹配前81%)(p < .001)。

关键数值与推荐

  • 多因素分析显示,三线治疗使用帕纳替尼是唯一与更好生存相关的独立因素(p = .003)。

临床怎么用

  • 原文结论认为帕纳替尼是经两种 prior TKI 治疗失败的CML-CP患者的优化治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients with chronic myeloid leukemia (CML). After failing second-generation TKI (2G-TKI), the optimal third-line therapy in chronic phase CML (CML-CP) is not well established. We analyzed 354 patients with CML-CP treated with a third-line BCR::ABL1 TKI at our institution, and in the PACE and OPTIC trials, and evaluated the outcome after alternate 2G-TKIs or ponatinib. We performed a propensity score matching analysis to compare outcomes and multivariate analysis to identify variables associated with survival. One hundred seventy-three (49%) patients received 2G-TKIs and 181 (51%) ponatinib. Patients in the ponatinib group had more cardiovascular risk factors (34% versus 19%) and higher disease burden (BCR::ABL1 transcript levels >1%, 165/175 [94%] versus 75/135 [55%]; p < .001) compared with the 2G-TKI group. Among the 173 evaluable patients treated with ponatinib, 89 (52%) achieved 2 + -log reduction of baseline transcripts (20% 2-log reduction and 32% 3 + -log reduction). Among the 128 evaluable patients treated with 2G-TKIs, 44 (34%) achieved 2 + -log reduction of baseline transcripts (13% 2-log reduction and 21% 3 + -log reduction). With a median follow-up of 46 months, the 3-year progression-free survival was 59% (60% before matching) with 2G-TKI and 83% (81% before matching) with ponatinib (p < .001). The 3-year survival was 83% (81% before matching) with 2G-TKI and 87% (89% before matching) with ponatinib (p = .03). By multivariate analysis, third-line therapy with ponatinib was the only independent factor associated with better survival (p = .003). In conclusion, ponatinib is an optimal treatment for patients with CML-CP failing two prior TKIs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023. PMID: 36683287. doi:10.1002/ajh.26852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。